An expert panel calls the requirement for tuberculosis testing before prescribing IL-17 and IL-23 biologics for psoriasis an ...

In older adults with psoriasis or psoriatic arthritis, use of two biologic classes was associated with lowest rates of serious adverse events than time off those drugs.

Psoriasis frequently progresses to PsA, and it has been uncertain whether drugs targeting TNF can delay or prevent it. This retrospective analysis examined progression rates in patients with severe ...

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...

Please provide your email address to receive an email when new articles are posted on . An analysis of more than 880,000 post-marketing reports found that all TNF inhibitors demonstrate a ...

It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time Results of a recent systematic literature review ...

Please provide your email address to receive an email when new articles are posted on . Patients with psoriasis treated with tumor necrosis factor inhibitors should adhere to a Mediterranean diet.

Despite challenges such as high costs and access barriers, the demand for effective, tailored therapies continues to rise, transforming the psoriasis treatment landscapeDublin, Nov. 26, 2025 (GLOBE ...

Patients with psoriasis who receive antibiotics may be more likely to discontinue their biologic therapy, a new study suggests. 1 In this French cohort study, the effect increased with multiple ...

In a recent review published in Signal Transduction and Targeted Therapy, researchers reviewed existing data on psoriasis etiopathogenesis and treatment. Psoriasis is a prevalent, chronic, ...